Harnessing AI For Drug Development – UK's BenevolentAI And MRCT Link
The hope artificial intelligence can revolutionize current drug discovery methods will be tested in a new collaboration between UK-based BenevolentAI and the medical research charity MRC Technology.
You may also be interested in...
Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.
Upsher-Smith Laboratories of the US is to buy the UK firm Proximagen for £223 million plus a potential £134 million through contingent value rights (CVRs) based on the success of two drugs in its pipeline.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.